向兔正常角膜滴注水性、油性和软膏剂剂型后酮咯酸的体内眼内可用性：技术说明
In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note.
作者信息
Malhotra Manjusha, Majumdar Dipak K
机构信息
Department of Pharmaceutics, Delhi Institute of Pharmaceutical Sciences and Research, Pushp Vihar, Sector III, New Delhi-110017, India.
出版信息
AAPS PharmSciTech. 2005 Oct 24;6(3):E523-6. doi: 10.1208/pt060365.
Abstract
In vivo ocular availability of ketorolac was evaluated following ocular instillation of aqueous, oil, and ointment formulations to normal corneas of rabbits and monitoring ketorolac concentration in aqueous humor by HPLC. Compared with aqueous drop, sesame and soybean oil drops of ketorolac provided higher ocular availability followed by ophthalmic ointment. The ointment formulation provided maximum sustained effect. Ketorolac aqueous drop with BAC and EDTA improved the rate of ocular absorption though not the extent.
摘要
通过向兔的正常角膜滴注水性、油性和软膏剂型的酮咯酸，并采用高效液相色谱法监测房水中酮咯酸的浓度，对酮咯酸的体内眼部可利用性进行了评估。与水性滴剂相比，酮咯酸的芝麻油和大豆油滴剂具有更高的眼部可利用性，其次是眼膏。软膏剂型提供了最大的持续效果。含苯扎氯铵和乙二胺四乙酸的酮咯酸水性滴剂提高了眼部吸收速率，但未提高吸收程度。
相似文献
1
In vivo ocular availability of ketorolac following ocular instillations of aqueous, oil, and ointment formulations to normal corneas of rabbits: a technical note.向兔正常角膜滴注水性、油性和软膏剂剂型后酮咯酸的体内眼内可用性：技术说明
AAPS PharmSciTech. 2005 Oct 24;6(3):E523-6. doi: 10.1208/pt060365.
2
In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment.酮咯酸从油基滴眼液和眼膏的体外角膜渗透情况。
Indian J Exp Biol. 1997 Dec;35(12):1324-30.
3
Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits.苯扎氯铵/乙二胺四乙酸对兔正常角膜和去上皮角膜滴入酮咯酸氨丁三醇后眼部生物利用度的影响。
J Pharm Sci. 1996 Apr;85(4):415-8. doi: 10.1021/js9504189.
4
Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: a technical note.酮咯酸的水性、油性和软膏制剂：对前列腺素E2诱导的眼部炎症的疗效及安全性：技术说明
AAPS PharmSciTech. 2006;7(4):96. doi: 10.1208/pt070496.
5
Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.新型环孢素 A 眼用胶束载体：体内角膜穿透、眼内分布和药效研究。
Eur J Pharm Biopharm. 2012 Jun;81(2):257-64. doi: 10.1016/j.ejpb.2012.02.014. Epub 2012 Mar 16.
6
Ocular topotecan pharmacokinetics following topical administration to rabbits for diffused anterior retinoblastoma.将拓扑替康局部应用于兔眼治疗弥漫性前部视网膜母细胞瘤后的药代动力学。
J Pharm Pharmacol. 2017 May;69(5):574-581. doi: 10.1111/jphp.12624. Epub 2016 Aug 30.
7
[Bioavailability of drugs applied to the eye externally].[眼部外用药物的生物利用度]
Klin Oczna. 1991 Jan;93(1):34-6.
8
Permeability of the cornea to topically applied drugs.角膜对局部应用药物的通透性。
Arch Ophthalmol. 1974 Apr;91(4):313-27. doi: 10.1001/archopht.1974.03900060323017.
9
Preparation and characterization of puerarin-dendrimer complexes as an ocular drug delivery system.葛根素-树枝状聚合物复合物的制备及表征作为一种眼部药物传递系统。
Drug Dev Ind Pharm. 2010 Sep;36(9):1027-35. doi: 10.3109/03639041003610799.
10
Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.局部用环孢素A及溶剂对荧光素角膜上皮通透性的影响
Doc Ophthalmol. 1995;91(1):49-55. doi: 10.1007/BF01204623.
引用本文的文献
1
Topical Ocular Drug Delivery: The Impact of Permeation Enhancers.眼部局部给药：渗透促进剂的影响
Pharmaceutics. 2025 Mar 31;17(4):447. doi: 10.3390/pharmaceutics17040447.
2
Pain Management Strategies before Pan-Retinal Photocoagulation for Diabetic Retinopathy: A Systematic Review.糖尿病性视网膜病变全视网膜光凝术前的疼痛管理策略：一项系统评价
J Ophthalmol. 2024 Aug 20;2024:6662736. doi: 10.1155/2024/6662736. eCollection 2024.
3
Relevance of Lipid-Based Products in the Management of Dry Eye Disease.基于脂质的产品在干眼症管理中的相关性。
J Ocul Pharmacol Ther. 2017 Nov;33(9):647-661. doi: 10.1089/jop.2017.0052. Epub 2017 Sep 28.
4
Design and Evaluation of Voriconazole Loaded Solid Lipid Nanoparticles for Ophthalmic Application.用于眼科应用的伏立康唑负载固体脂质纳米粒的设计与评价
J Drug Deliv. 2016;2016:6590361. doi: 10.1155/2016/6590361. Epub 2016 May 12.
5
Chondroitin sulfate-chitosan nanoparticles for ocular delivery of bromfenac sodium: Improved permeation, retention, and penetration.用于溴芬酸钠眼部给药的硫酸软骨素-壳聚糖纳米颗粒：改善渗透、滞留和穿透性。
Int J Pharm Investig. 2016 Apr-Jun;6(2):96-105. doi: 10.4103/2230-973X.177823.
6
Topical ocular delivery of NSAIDs.非甾体抗炎药的眼部局部给药。
AAPS J. 2008 Jun;10(2):229-41. doi: 10.1208/s12248-008-9024-9. Epub 2008 Apr 25.
7
Aqueous, oil, and ointment formulations of ketorolac: efficacy against prostaglandin E2-induced ocular inflammation and safety: a technical note.酮咯酸的水性、油性和软膏制剂：对前列腺素E2诱导的眼部炎症的疗效及安全性：技术说明
AAPS PharmSciTech. 2006;7(4):96. doi: 10.1208/pt070496.
本文引用的文献
1
Effect of preservative, antioxidant and viscolizing agents on in vitro transcorneal permeation of ketorolac tromethamine.防腐剂、抗氧化剂和增粘剂对酮咯酸氨丁三醇体外角膜渗透的影响。
Indian J Exp Biol. 2002 May;40(5):555-9.
2
Pain reduction after laser in situ keratomileusis with ketorolac tromethamine ophthalmic solution 0.5%: a randomized, double-masked, placebo-controlled trial.0.5%酮咯酸氨丁三醇滴眼液用于准分子原位角膜磨镶术后的镇痛效果：一项随机、双盲、安慰剂对照试验
J Refract Surg. 2002 Mar-Apr;18(2):140-4. doi: 10.3928/1081-597X-20020301-07.
3
Topical ketorolac tromethamine 0.5% ophthalmic solution in ocular inflammation after cataract surgery.0.5% 酮咯酸氨丁三醇局部用滴眼液用于白内障手术后的眼部炎症。
Ophthalmology. 2001 Feb;108(2):331-7. doi: 10.1016/s0161-6420(00)00543-1.
4
Ketorolac tromethamine 0.5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial.酮咯酸氨丁三醇0.5%滴眼液治疗白内障术后中重度眼部炎症：一项随机、赋形剂对照临床试验
Am J Ophthalmol. 1999 Mar;127(3):253-9. doi: 10.1016/s0002-9394(98)00413-9.
5
In vitro transcorneal permeation of ketorolac from oil based ocular drops and ophthalmic ointment.酮咯酸从油基滴眼液和眼膏的体外角膜渗透情况。
Indian J Exp Biol. 1997 Dec;35(12):1324-30.
6
Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits.苯扎氯铵/乙二胺四乙酸对兔正常角膜和去上皮角膜滴入酮咯酸氨丁三醇后眼部生物利用度的影响。
J Pharm Sci. 1996 Apr;85(4):415-8. doi: 10.1021/js9504189.
7
Use of flurbiprofen to inhibit corneal neovascularization.使用氟比洛芬抑制角膜新生血管形成。
Arch Ophthalmol. 1980 Jun;98(6):1102-5. doi: 10.1001/archopht.1980.01020031092017.
8
Effects of calcium chelating agents on corneal permeability.钙螯合剂对角膜通透性的影响。
Invest Ophthalmol Vis Sci. 1985 Jan;26(1):110-3.
9
Ocular bioavailability and tissue distribution of [14C]ketorolac tromethamine in rabbits.兔体内[14C]酮咯酸氨丁三醇的眼内生物利用度和组织分布
J Pharm Sci. 1987 Apr;76(4):289-94. doi: 10.1002/jps.2600760405.
10
Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema.0.5%酮咯酸氨丁三醇滴眼液治疗慢性无晶状体眼和人工晶状体眼黄斑囊样水肿的有效性
Am J Ophthalmol. 1987 Apr 15;103(4):479-86. doi: 10.1016/s0002-9394(14)74268-0.
Zotero 插件